info@afternoonnews.in +91 98940 - 95096

Today Date : Monday, June 24, 2024

Apollo Cancer Centre introduces CyberKnife® S7™ FIM Robotic Radio Surgery System

Apollo Cancer Centre introduces CyberKnife® S7™ FIM Robotic Radio Surgery System

Ushering in another new era in healthcare, Apollo Cancer Centre, Chennai has introduced South Asia’s first CyberKnife—CyberKnife® S7™ FIM Robotic Radio Surgery System— offering a revolutionary treatment modality of cancerous and non-cancerous tumors. The introduction of the CyberKnife System marks a transformative moment for cancer care and technology, and Apollo Cancer Centre has set a new standard by being the first in South Asia to introduce this ground-breaking technology. 

Dr Mahadev Potharaju, Senior Consultant  Radiation Oncology, elaborated CyberKnife® S7™ FIM treatments are typically performed in 1 to 5 sessions. The treatment duration typically ranges from 30 to 90 minutes, during which 100 to 200 radiation beams are administered from various angles. Each beam lasts for approximately 10 to 15 seconds. Treatment sessions are non-invasive outpatient procedures, and no anaesthesia or incisions are required, enabling most patients to continue with daily activities over the course of treatment.

Dr Ratnadevi R, Senior Consultant - Radiation Oncology, said, “CyberKnife S7 FIM is most effective in treating common benign lesions in the brain like schwannoma, meningioma and AVM in a non-invasive way so that we can avoid open surgery. It is the only system in the world to provide motion-synchronized, real-time treatment delivery adaptation for the treatment of any type of moving target. 

Dr Shankar Vangipuram, Senior Consultant  Radiation Oncology stated, The CyberKnife® S7™ FIM System redefines the future of radiation therapy, combining speed, precision and Synchrony® AI-driven, real-time target tracking with dynamic delivery to deliver precise hypo fractionated SRS/SBRT treatments for a wider range of indications which include benign brain tumors, brain metastases, select medically refractory functional indications: trigeminal neuralgias, cluster headaches, tremors, lesional epilepsy & select extra cranial inoperable (due to medical or technical reasons) cancers of lung,  pancreas, liver, prostate, recurrent Head and neck cancers.”